Fig. 2From: Correcting for misclassification and selection effects in estimating net survival in clinical trialsDistributions of net survival estimations carried out with cause-specific versus population-based methods (KM, Cox, and wNA vs. PP and RBS) in prostate cancer patients who received: (a) low-dose (solid line) diethylstilbestrol (0 and 0.2 mg/d); (b) high-dose (dashed line) diethylstilbestrol (1 and 5 mg/d)Back to article page